News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results for the First Half 2013



8/22/2013 6:33:32 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Hørsholm, Denmark, 21 August, 2013

Veloxis Pharmaceuticals announces financial results for the first half 2013

Highlights:

-- LCP-Tacro(TM) has successfully demonstrated non-inferiority compared to tacrolimus (Prograf(R); Astellas Pharma) in its Phase III clinical trial, Study 3002. The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf(R) as the comparator, met its primary efficacy and primary safety endpoints.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES